CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients

Eva Castellano1, Célia Samba1, Gloria Esteso1, Laura Simpson2, Elena Vendrame2, Eva M. García-Cuesta1, Sheila López-Cobo1, Mario Álvarez-Maestro3,4, Ana Linares4, Asier Leibar4, Thanmayi Ranganath2, Hugh T. Reyburn1, Luis Martínez-Piñeiro3,4, Catherine Blish2,5 and Mar Valés-Gómez1,2*

1Department of Immunology and Oncology, National Centre for Biotechnology (CNB) Spanish National Research Council (CSIC), Madrid, Spain, 2Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States, 3Urology Department, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain, 4Urology Unit, Infanta Sofía Hospital, Madrid, Spain, 5Chan Zuckerberg Biohub, San Francisco, CA, United States

High grade non-muscle-invasive bladder tumours are treated with transurethral resection followed by recurrent intravesical instillations of Bacillus Calmette Guérin (BCG). Although most bladder cancer patients respond well to BCG, there is no clinical parameter predictive of treatment response, and when treatment fails, the prognosis is very poor. Further, a high percentage of NMIBC patients treated with BCG suffer unwanted effects that force them to stop treatment. Thus, early identification of patients in which BCG treatment will fail is really important. Here, to identify early stage non-invasive biomarkers of non-responder patients and patients at risk of abandoning the treatment, we longitudinally analysed the phenotype of cells released into the urine of bladder cancer patients 3-7 days after BCG instillations. Mass cytometry (CyTOF) analyses revealed a large proportion of granulocytes and monocytes, mostly expressing activation markers. A novel population of CD15+CD66b+CD14+CD16+ cells was highly abundant in several samples; expression of these markers was confirmed using flow cytometry and qPCR. A stronger inflammatory response was associated with increased cell numbers in the urine; this was not due to hematuria because the cell proportions were distinct from those in the blood. This pilot study represents the first CyTOF analysis of cells recruited to urine during BCG treatment, allowing identification of informative markers associated
with treatment response for sub-selection of markers to confirm using conventional techniques. Further studies should jointly evaluate cells and soluble factors in urine in larger cohorts of patients to characterise the arms of the immune response activated in responders and to identify patients at risk of complications from BCG treatment.

**KEYWORDS**
bladder cancer, BCG - Bacille Calmette-Guérin vaccine, granulocytes, leukocytes, immune response, mass cytometry (CyTOF), urine cells

---

**Introduction**

Bladder cancer is the ninth most commonly occurring cancer in the world (1) and the fifth most commonly diagnosed in Europe according to GLOBOCAN 2018 [Global Cancer Observatory (GCO), http://gco.iarc.fr/]. 70% of cases correspond to non-muscle invasive bladder cancer (NMIBC), that can recur and eventually become more aggressive and invade deeper layers of the bladder wall. High-grade NMIBC (classified as Tis or Ta-1G3 tumours) is treated with transurethral resection followed by intravesical instillations of Bacille Calmette-Guérin (BCG), an attenuated strain of *Mycobacterium bovis* originally developed as vaccine for tuberculosis (2, 3). The treatment was approved by the FDA decades ago and consists of weekly BCG instillations into the patient’s bladder, so that mycobacteria are applied directly to the tumour site. Therapy duration varies between different hospitals, but always comprises an induction phase of 6 weekly instillations and a maintenance phase comprising at least one year of 2-3 weekly instillations alternating at 3, 6 and 12 months. BCG represents the first successful immunotherapy, since the response involves the activation of the immune system and a majority of patients respond well to this treatment and are free from relapse for at least three years after treatment. However, 30 to 40% of patients experience recurrence or progression and there are still no predictive methods for an early identification of non-responder NMIBC patients (4–6). Usually, failure of treatment is identified when the tumour has grown enough to either generate a positive urine cytology or a macroscopic mass that can be seen by direct inspection of the bladder with cystoscopy or by means of imaging with ultrasound or CT scan. Thus, the identification of biomarkers that allow early identification of non-responder NMIBC patients is a clear unmet need. Additionally, although BCG treatment is effective, a high number of patients suffer adverse effects due to the presence of living bacteria in the bladder, such as irritation or mild fever, and a small percentage of them can even suffer systemic problems associated with the treatment (7, 8), such as sepsis, pulmonary or urogenital infections. Research is still needed in this area to prevent these severe side effects and to adjust the adequate BCG dose to each particular patient depending on their immune response (9).

Several clinical and pathological parameters as well as soluble immune factors have been proposed to have value as prognostic markers for NMIBC patients. Urologists usually classify patients following models widely known for prediction of tumour recurrence and progression, and risk tables have been elaborated by the European Organization for Research and Treatment of Cancer (EORTC) (10, 11) and the Club Urológico Español de Tratamiento Oncológico (CUETO) (12). These models are based on clinical parameters such as histological grading, pathological stage, tumour multiplicity, etc., but their predictive power is still insufficient. Laboratory-based research has proposed using other variables such as the amount of cytokines in urine (13, 14) or the combination of the concentration of soluble factors in urine with clinical data (CyPRIT) (15). However, their use is still not in place in the clinics since studies in larger cohorts are needed.

Due to difficulties in studying immune responses to tumours in humans, many laboratories have addressed these questions in animal models or *in vitro* experiments. In these studies, researchers have concluded that instillations with BCG result in immune cell infiltration in the bladder as a consequence of the inflammatory response (16, 17). *In vitro* studies have investigated the effect of BCG on different immune cell types; granulocytes (18), dendritic cells (19) and natural killer (NK) cells (20–22), which become activated in response to mycobacteria. For example, we have recently described an anti-tumour specific population of CD56^{bright} CD16^{-} NK cells after *in vitro* exposure of peripheral blood mononuclear cells (PBMCs) to BCG that display cytotoxic activity against bladder cancer cells (23). Pioneering studies 30 years ago revealed that the number of cells in urine significantly increased 24 hours after BCG administration and that neutrophils were a predominant
Materials and methods

Patient recruitment and study approval

A prospective study to analyse the immune response of BCG-treated NMIBC patients was designed and, a total of 44 urine samples were collected at different times of treatment from patients at either Hospital Infanta Sofia or Hospital Universitario La Paz (Madrid, Spain), n=14; mean age 72 years (Figure 1A) (Table 1). Enrolment occurred between the years 2015 and 2016 and patients with bladder cancer at the stage Ta/T1 G3 or CIS, at diagnosis, were selected. Follow-up was done for an average of 2.2 years. No patient had recurrence. P26 suffered urine infection; P25 died due to brain haemorrhage; P46 died due to lung cancer; P43 and 48 had low number of cells in the only sample obtained from these patients, so they were not analysed. Because immune cells are not present in urine of healthy donors or mitomycin C-treated bladder cancer patients (our usual control), no control group was included. The experiments were conducted with the understanding and written informed consent of each participant and approved by local and regional ethical committees (Institutional Review Boards, numbers and dates: CEI La Paz Hospital HULP-1067 Feb 8th 2011; revised by CEI Infanta Sofia Hospital and CSIC Local Ethical Committee; HULP-2338, April 25th 2016). The experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.

Sample handling

Samples were obtained by spontaneous micturition by patients prior to BCG instillation at the clinic. Usually, within 2 hours, samples were centrifuged at 400 x g to separate cells and crystals from supernatants and washed with PBA [PBS containing 0.5% bovine serum albumin (BSA), 1% foetal bovine serum (FBS) and 0.1% sodium azide]. Cells were resuspended in PBA, counted and one aliquot was stained for flow cytometry immediately. The rest of the cells were washed by centrifugation at 200 x g and cryopreserved in FBS containing 10% DMSO at -80°C in aliquots until further analysis.

Fluorescence microscopy

Cells were allowed to adhere on poly-L-lysine coated slides. Attached cells were then fixed with 4% p-formaldehyde for 10 min at RT, and stained with DAPI during 10 min at RT. After washing and mounting they were visualised using a DMI 6000B (Leica) photonic microscope at the confocal microscopy unit of the CNB.
Electron microscopy

Washed urine cells were resuspended in 0.4 M HEPES buffer pH 7.2 and centrifuged at 200 x g before being fixed using 2% glutaraldehyde/1% tannic acid in HEPES buffer, 2 h at room temperature. The pellet was centrifuged to remove the fixing solution and resuspended in HEPES buffer and solidified by the addition of 2% agarose. After 1h incubation in 1% osmium tetroxide/0.8% potassium iron cyanide at 4°C, and three washes, they were incubated with 2% uranyl acetate and lead citrate. The pictures show examples of cells with different morphology and integrity observed in different patients. Cells from bladder cancer patients receiving intravesical instillations of BCG (Ta/T1G3 or CIS, mean age 68.5 years) were analysed. Samples were obtained 3 and 5 days after BCG for a few patients.
citrate and observed under a Jeol JEM 1011 a 100 kV microscope. Images were taken with a Gatan Erlangshen ES100W camera at the electron microscopy unit of the CNB.

**Flow cytometry**

Cells washed in PBA were incubated with conjugated antibodies against surface markers at 4°C for 30 minutes in the dark [CD15 PB Biolegend #394704 Clone MMA, CD16 PC7 Biolegend #302016 Clone 3G8, CD14 A700 Biolegend #301822 Clone M5E2, HLA-DR PE Immunotech #1639 Clone IMMU-357, CD11c APC Biolegend #301614 Clone 3.9, CD3 APC Beckman coulter #IM2467 Clone UCHT1, CD19 ECD Beckman coulter #A07770 Clone J3-119, CD8 PC7 Biolegend #344712 Clone SK1, CD4 PE Immunotools #21278044 Clone EDU-2]. Cells were washed in PBA and analysed using either Gallios or CytoFLEX Flow Cytometers (Beckman Coulter). For urine flow cytometry, certain antibody clones did not work, so they were carefully selected; for example, CD3 OKT3 clone was changed for UCHT1. Analysis of the experiments was performed using Kaluza software (Beckman Coulter). In certain experiments, to keep cells intact after staining, they were fixed with 1% p-formaldehyde for 10 min at room temperature (RT).

**Mass cytometry**

Urine cells were thawed into 9 ml of 10% FCS-RPMI medium supplemented with 10 IU/ml Benzonase (Novagen 70664-3), counted and viability determined by trypan blue exclusion. Staining was performed in 96-well deep-well plates (Sigma) as previously reported (25), briefly, 1-2·10^6 cells were washed with 600 µl CyFACS (PBS supplemented with 2% BSA, 2 mM EDTA, and 0.1% sodium azide) and resuspended in 200 µl for staining cells were first incubated with 25 µM cisplatin (Enzo Life Sciences), then stained with a panel of surface antibodies (Supplementary Table 2). After that, cells were fixed and permeabilised (BD FACS Lyse, BD FACS Perm II), followed by intracellular antibody staining. Finally, cells were incubated with Ir-intercalator (DVS Sciences) and washed extensively using filtered PBS and metal free milli-Q water. Calibration Beads (EQ™ Four Element CB) were added before the sample was acquired in a mass cytometry instrument (Fluidigm). Antibodies were conjugated using MaxPar X8 labeling kits (DVS Sciences). Mass cytometry experiments were performed at the Stanford School of Medicine, Fairchild Science Bldg.

**Data normalisation, viSNE analysis and hierarchical clustering**

To ensure the homogeneity of data obtained at mass cytometry across time, data normalisation was performed using Normaliser v0.3 [https://github.com/nolanlab/bead-normalization/wiki/Installing-the-Normalizer](https://github.com/nolanlab/bead-normalization/wiki/Installing-the-Normalizer) (26).

Data were visualised with viSNE, implemented in Cytobank (https://www.cytobank.org/) (27).

Several viSNE runs were performed grouping different samples (either according to patient or time of treatment). Selection of populations within viSNE was done as follows: live cell populations were first selected gating intact cells based on 191Ir (DNA-1) vs 193Ir (DNA-2), then live singlets were gated based on the parameters corresponding to event length, beads and cisplatin (26). For certain analyses, indicated in the main text, a further gating was performed to select CD66b+ cells. Equal numbers of cells (100,000) were selected.

After gating, viSNE analyses were launched selecting the channels for the population separation. Most analyses were performed selecting the lineage markers: CD19, CD4, CD8, CD3, CD15, CD14, NKp46, CD66b, CD56, HLA-DR and CD33. In the case of the analysis performed after gating the CD66b+ population, the parameters selected to launch the viSNE analysis were CD11b, CD35, CD63, CD11c, CD14, CD107a. Different populations were manually gated on t-SNE1 vs t-SNE2 plots and median expression of the different markers was used to group clusters with similar expression profiles.

Hierarchical cluster of arrays was performed using cluster 3.0, selecting the average linkage clustering method. Java TreeView was used for visualisation, heat map was generated in GraphPad.

**TABLE 1** Patient demographics and clinical features.

| Gender | N | %  |
|--------|---|----|
| Male   | 12| 85.7 |
| Female | 2 | 14.3 |

| Age     | N | %  |
|---------|---|----|
| More than 71 | 6 | 42.9 |
| 61-70    | 7 | 50.0 |
| 60 or less | 1 | 7.1 |

| Size    | N | %  |
|---------|---|----|
| ≥3 cm   | 2 | 14.3 |
| <3 cm   | 7 | 50.0 |
| N/A     | 5 | 35.7 |

| Tumour number | N | %  |
|---------------|---|----|
| <3           | 10| 71.4 |
| ≥3           | 1 | 7.1 |
| N/A          | 3 | 21.4 |

| Primary  | N | %  |
|----------|---|----|
| Recurrent  | 4 | 28.6 |

| Treatment delayed due to side effects | N | %  |
|--------------------------------------|---|----|
| stroke                               | 2 | 14.3 |

| Stop due to side effects | N | %  |
|--------------------------|---|----|
| stroke                  | 1 | 7.1 |

| Recurrence: n | N | %  |
|---------------|---|----|
| n             | 0 | 0 |

| Progression | N | %  |
|-------------|---|----|
| progression | 0 | 0 |
qPCR

Urine was centrifuged and the cell-containing pellet was washed with PBS. RNA was extracted from dry pellets using RNeasy Kit (Qiagen). cDNA synthesis was carried out using random hexamers and SuperScript II RNase (Invitrogen). For qPCR, 3 μl of cDNA (diluted 1:10) were mixed with 5 μl of reaction mix [PyroTaq EvaGreen qPCR Mix Plus (ROX) (CMBTM) and both forwards and reverse primers at 0.5 mM] in 384-well plates. Wells containing 3 μl of water instead of cDNA were used as negative controls. For each amplification, b-actin was included as reporter gene. Amplification reactions were set in triplicates and performed in a QuantStudio5 (Applied Biosystems) instrument with a 1 min cation (15 s at 95°C and 1 min at 60°C). Results were analysed with QuantStudio™ Design & Analysis 1.4.3 Software and Microsoft Excel. Fold change was calculated relative to the cycles of b-actin (2-ΔΔCt). Plots were represented using GraphPad Prims 8 Software (GraphPad Software, USA, www.graphpad.com). The following primers were used: CD56 Forward: TCTGATGGGACACATGTTG; CD56 Reverse: TGGCTCTTCAGGGTCAGCA CA; CD3g Forward: GGATGTATCAGTGTAAAGG; CD3g Reverse: CATGAGGTTGGAAGCTTGTGAGC; CD14 Reverse: GCATGGATCTCACATCAGAGATCAA; b-actin Forward: CCCAGCACAATGAAGTAGACCC; CD14 Forward: ACGCCAGAAC GTTGTGAGC; CD14 Reverse: GCATGGATCTCACATCAGAGATCAA; b-actin Reverse: CGATCCACACGGAGTACTTG; CD66b Forward: GGGATGTATCAGTGTAAAGG; CD66b Reverse: ACTGTTGAGGTTGAGGAGGC.

Results

Analysis of the immune cells present in bladder cancer patient urine 7 days after BCG instillation

Bladder cancer patients start BCG instillations a few weeks after transurethral resection, and once haematuria has resolved. In a previous study of cytokines released to urine during BCG treatment (14), a clear increase in urinary cells was observed once instillations started. Although it was possible to count a few thousand cells per ml of urine in some patients at the beginning of treatment, most patients had urinary cell numbers above 10⁷/ml only after they had started receiving BCG instillations. This study was therefore designed to explore whether the identity of the cells recruited to urine could provide information on the immune response stimulated by mycobacteria. Because the treatment involves many cycles of instillations, when possible, several samples were obtained from the same patient after different cycles of instillations. As we were interested in the cells recruited after the initial inflammation has been resolved, samples were obtained between 2 and 7 days after instillations (Supplementary Table 1). The number and shape of urinary cells varied between donors, however, hematopoietic-like, as well as flat, fibroblast-like cells could consistently be observed by light and electron microscopy in these preparations (Figure 1B).

To investigate the nature of the cellular immune response occurring in BCG-treated NIMBC patients, initial experiments were designed to assess the phenotype of urinary cells by multiparametric flow cytometry. Samples were collected several days after instillation with BCG, thus allowing the evaluation of cell populations persisting after the initial inflammation. Initial analyses of Forward Scatter/Side Scatter (FSC/SSC) plots showed that urinary cells differed from those in peripheral blood, presumably due to the different osmolarity and pH conditions (Figure 1C). Despite the unsightly flow cytometry plots, it was clear that certain antibodies were staining the cells; in particular, CD14, and CD16 were easily observed in many of the samples analysed (Figure 1D). These results suggested that urine immune cells could be a useful source of information about the level of inflammation and anti-tumour response of bladder cancer patients several days after treatment with BCG, specifically after one week, since this point coincides with when the patients have to re-visit the clinic for the next BCG instillation. Thus, it was important to optimise a method to evaluate multiple parameters in these cell populations.

Flow cytometry experiments posed a number of technical problems, which could be due to the hypoxic conditions of urine to which the cells had been exposed for several hours prior to staining. Some antibodies failed to stain and thus different mAb clones were carefully selected and tested. Additionally, the events occurring in BCG-treated NIMBC patients, initial experiments were carried out to optimise the methodology for flow cytometry of cells in urine. In hypoxic environments, like urine, cells have their metabolism skewed towards glycolysis and accumulate nicotinamide dinucleotides (NADH and FAD) which have fluorescence peaks in the range of the fluorophores used for flow cytometry (NADH Ex Max = 350nm; FAD Ex Max = 450nm; NADH Em Max = 450nm, FAD Em Max 530nm) (28). Thus, fluorescence artefacts were reduced by turning off the green channels in the flow cytometer, so that endogenous fluorescence would not interfere. In parallel, DNA content was determined by staining with Hoechst dye and a gating strategy was established using all this information.
(Supplementary Figure 1A). To validate the specificity of antibody staining, blocking experiments were carried out. Non-specific staining was not observed, since blockade of Fc receptors with either human Ig or human serum did not decrease signal (Supplementary Figure 1B).

These experiments demonstrated that urine samples from bladder cancer patients contained immune cells that could be further characterised by flow cytometry.

Mass cytometry can be used to detect and phenotype urinary cells in BCG-treated patients

In order to explore a large number of markers using the limited number of cells available per patient, urinary cells were analysed by CyTOF, which has the advantage that it does not rely on fluorescence, and thus allowed us to overcome the technical challenges caused by the autofluorescence observed in the conventional flow cytometry experiment.

CyTOF was used to perform a comprehensive study of multiple parameters in urinary cells from different bladder cancer patients at different time points, focussing mainly on analysing the initial cycle of instillations to obtain data that could help further flow cytometry studies, a technique that is more readily transferred to clinical laboratories.

Since there were no reports on handling urinary cells for mass cytometry analysis, the first challenge was to confirm whether these hypoxic, previously frozen urine cells could be analysed using this technology. To do so, two samples from different donors were thawed into cold RPMI containing 20% FCS and benzonase. Cell viability was above 80% and aliquots of 0.5·10⁶ urine cells were stained for mass cytometry using a FCS and benzonase. Cell viability was above 80% and aliquots of different donors were thawed into cold RPMI containing 20% analysed using this technology. To do so, two samples from whether these hypoxic, previously frozen urine cells could be mass cytometry analysis, the readily transferred to clinical laboratories.

Once it had been established that CyTOF could be used to phenotype cells released in the urine of BCG-treated NMIBC patients, 44 samples obtained at different time points of the treatment from 12 different BCG-treated bladder cancer patients were stained and analysed by CyTOF (Table 1). The data obtained in different days were normalised (Supplementary Figure 2), and viSNE was used to visualise the distribution of cell phenotypes (27) (See methods). Several viSNE analyses were done, grouping different samples in each case, so that we could compare initially the samples corresponding to a given treatment day, and then grouping the samples corresponding to a particular donor.

Before examining viSNE data in detail, the maps were used to verify antibody binding specificity and to confirm that the markers expressed by different cell populations were in general consistent with the molecules expected to be expressed by particular lineages (Figures 2B–D). As expected, the CD66b population, corresponding to CD15+ granulocytes, did not express lymphocyte markers such as CD19, CD3 or CD56 or the myeloid marker CD14, that co-localised with CD11c. Similarly, CD3+ T lymphocytes could be divided into CD4+ and CD8+ and these populations were negative for monocyte or granulocyte markers. EpCAM was not expressed in hematopoietic cells. CD56+CD16+ NK cells also expressed the NK markers CD94, NKG2A, but not CD8 or CD4 (Figure 2C). In some cases, a small population that showed nonspecific binding of many different lineage markers was identified, suggesting an artefact of staining. These cells were eliminated from further analyses (Figure 2D).

Thus, although cells recruited to urine had suffered extreme conditions, their phenotype could still be analysed using CyTOF.

Urine obtained from BCG-treated patients at weeks 0 and 6 contains heterogeneous cell populations

To have a first broad view of the different cell types that could be found at different stages of the BCG treatment, samples obtained before any instillation (time zero) (Figure 3A) and before the 6th instillation (Figure 3B) were compared using viSNE. Most patients did not have cells before starting BCG instillations and only 3 samples corresponding to time zero were available to analyse cells (Supplementary Table 1). The presence of cells in urine at this stage is probably due to the inflammatory process and healing of the post-surgical bladder wound. It is unlikely that these cells correspond to simple haematuria because the percentages of leukocytes observed in these samples were not consistent with the composition of blood populations.
The abundance of different cell populations was represented in density maps and the relative amount of the different population and activation markers were visualised in colour maps (Figure 3). At time zero, the distribution of cells analysed in the three different patient samples differed. One patient (P25) had a considerable population of lymphocytes, mainly NK cells and some CD3+ lymphocytes, while the other two patients (P26 and P31) had primarily granulocytes and monocytes (Figure 3A).

Before receiving the 6th instillation, myeloid and granulocyte populations predominated in all patients (Figure 3B). A small percentage of monocytes and even smaller proportions of CD3+ lymphocytes and NK cells could be detected in most samples. B cells were generally absent. Cells not binding any of the antibodies used against immune populations, probably epithelial cells, were also abundant and could be visualised by electron microscopy (Figure 1B).
CD66b+ granulocytes in urine of bladder cancer patients are a heterogeneous population

The first analyses shown above, comparing two different time points of the BCG treatment, revealed the general characteristics of the cells released into urine of bladder cancer patients, with some heterogeneity among samples. However, a second level of heterogeneity can be considered in this study, that is donor-to-donor variation. To further explore the combination of different markers and populations present in urine samples from one patient during different stages of the treatment, viSNE analyses were carried out after grouping all the available samples for each one of the patients (Figure 4A, top rows). This second analysis was done to evaluate the effect of time in cell heterogeneity for each donor.

It was surprising to find CD66b+ cells that co-expressed CD14 and CD11c in many different patients. Further, it was evident that the abundant granulocyte population was composed of several subpopulations which expressed different levels of other molecules such as CD16, HLA-DR and CD11c. For better resolution of this unexpected population, we first gated on CD66b+ cells and then ran viSNE analysis just on this population for each patient (Figure 4A, bottom rows). It was
then possible to identify CD14+ cells within the gate of CD66b+ granulocytes.

To explore the different markers expressed by CD66b+ cells, a heat map was built and used to compare the markers expressed by CD66b+ and by lymphocyte populations (Figure 4B). This was done to aid in the classification of cell populations and to identify similar populations in different samples and patients; thus, this heat map does not show a proportional clustering of the populations enriched during treatment, but rather is a tool to help visualising the patterns of expression contained in the large number of samples analysed. Using this visualisation tool, it was confirmed that CD3+ cells also expressed CD45 and CD7, could express either CD4 or CD8, and were negative for other markers such as CD19, CD66b, CD11b or CD11c. Myeloid cells were CD14+ CD11c+ HLA-DR+, but CD15- and CD3-, while CD66b+ cells could appear either as classical granulocytes CD14- HLA-DR- CD11clo, or CD14+ HLA-DR+ CD11c+, all of them being negative for lymphocyte markers. It was also possible to identify populations with non-specific binding of antibodies that were excluded from any further analyses. Interestingly, CD66b+ CD15+ cells also expressed CD107a and CD69, corresponding to activated granulocytes. Different levels of CD66b expression resulted in two types of granulocytes that were designated dim and bright; however, they also could be distinguished by different levels of HLA-DR, CD16 and CD11c expression. Unexpectedly, a hybrid population with features of both granulocytes and monocytes (CD14+ CD15+ cells) was also identified in these samples. CD14+ CD15+ cells have been described previously in cancer patients. This phenotype could correspond to antigen presenting cells-like hybrid tumour associated neutrophils (APC-like TAN) in which markers for both granulocytes (CD11b, CD66b, CD15) and monocytes (CD33, CD14, HLA-DR, CCR7, CD86, CD20) co-exist.

T lymphocytes, expressing CD45, CD7, CD3 and either CD8 or CD4, were only found in a few samples. Similarly, only a few samples contained NK cells. When detected, lymphocytes were usually positive for activation markers and the combination of markers showed consistency within each population.

**APC-like tumour associated neutrophils were identified in freshly isolated urine cells**

Since several populations observed in CyTOF data using viSNE revealed unexpected combinations of markers (Supplementary Figure 3A), these phenotypes were confirmed by manual analysis (Supplementary Figure 3B) and new flow cytometry analysis (Supplementary Figure 3C). Additionally, samples from three new different patients receiving the 6th BCG instillation (Week 6), were also analysed by flow cytometry, revealing again three populations: CD15+ CD14+, CD15+ CD14+, CD15+ CD14+ (Figure 5). This new experiment, performed with freshly isolated urine cells from three patients in parallel allowed flow cytometry discrimination between CD14+CD15+ TAN and CD14+CD15- monocytes. CD14+CD15+ TAN and CD14+CD15- monocytes expressed CD11c and HLA-DR while the granulocyte population CD15+...
CD14 did not express these markers. Each subpopulation was also easy to identify in the FSC/SSC region and was present in different amounts in the three patient samples stained in parallel. These data are consistent with those obtained by CyTOF. Looking at the combinations of CD66b, CD16, CD11c and HLA-DR, several cell populations were identified: monocytes CD66 CD11c HLA-DR CD16; granulocytes CD66 CD11c HLA-DR CD16; and APC-like neutrophils CD66 CD11c HLA-DR CD16. It was also clear by flow cytometry that different patients have different percentages of each population within total urine cells. The percentages of immune populations obtained were manually gated to confirm the subpopulations identified (Supplementary Figure 4). Interestingly, this analysis revealed that a large number of cells were not stained with the immune population markers, and these cells likely correspond to either tumour cells or epithelial cells from the genito-urinary tract.

To further confirm the lineage of urinary cells found by CyTOF and flow cytometry, gene expression was tested by qPCR. Dry cell pellets were used to extract RNA and, after cDNA synthesis, qPCR experiments were performed using primers for the main lineage markers, comparing their amplification cycle with that of the reporter gene, β-actin. To validate the primers, gene amplification from PBMC or purified granulocytes was performed and used for comparison (Figure 6). CD14 and CD66b expression were clearly detected in most of these samples, while CD3 and CD56 were only detected in a few patients and samples. It is interesting to note that CD66b was amplified more efficiently in cells from urine than in purified neutrophils from peripheral blood. This probably indicates that the former are active cells while granulocytes are usually quiescent and short lived in healthy donor peripheral blood. It is also possible to detect by PCR some markers that were not so evident by flow cytometry or CyTOF, suggesting the loss of epitopes or cell death.

**Urinary cell distribution can identify patients with unusual treatment outcomes**

Notably, P25, P26 and P31, in contrast to the majority of patients, already had immune cells in the sample collected at time zero, ie before receiving any BCG instillations (Figure 3) and higher number of cells were collected during the course of treatment (Supplementary Table 1). Interestingly, these three patients had different clinical courses compared to the other patients. P25 developed uveitis and died due to a brain...
haemorrhage. Whether this could be a case of a rare complication due to BCG is unclear; there are 15 cases of ocular inflammation reported after intravesical BCG instillations, 4 of them with confirmed Mycobacterial invasion (30). The treatment course of P26 was complicated by fever and urinary tract infection. P31 also had a gynaecologic tumour and thus had received radiotherapy. The composition of immune cells was also different in these three patients. P25 had a large NK cell population at time zero, that disappeared after BCG instillations, while P26 and P31 mainly had granulocytes at time zero. P26 mainly had high percentage of monocytes during the course of the treatment while P31 had large populations of both classical and APC-like granulocytes.

Discussion

Here, we report the first CyTOF analysis of cells released into urine in the context of BCG treatment for bladder cancer. We have also optimised flow cytometry protocols for the analysis of these cells and compared these data with qPCR analysis. With the aim of studying immune infiltration in bladder cancer patients, using a minimally invasive procedure, we analysed the cells in 44 urine samples obtained from 12 different bladder cancer patients at different time points during treatment. The majority of these samples were collected 3-7 days after receiving the previous BCG instillation, so that the initial inflammation response was already cleared. This study has allowed the characterisation of several immune cell types that could be involved in the immune/inflammatory response in these cancer patients, including an APC-like neutrophil population.

Several technical challenges had to be overcome for this pilot study, and data interpretation had to take into account several factors: 1) cells had been under hypoxic conditions and osmotic stress for several hours before collection, thus, certain epitopes might have been lost and autofluorescence increased; and 2) because urine only contains scarce cells in healthy donors, there is no healthy donor control, thus the methodology had to be set up comparing with PBMC. In addition to these problems, it was impossible to anticipate either the proportion of cell subpopulations expected or the epitopes that could be altered due to the cancer microenvironment.

The use of CyTOF allowed us to perform a broad screening of the cells released into urine because it is a highly multiplexed technique that permits the analysis of multiple markers on a limited number of cells, thus increasing the amount of information obtained in each experiment. Importantly, CyTOF is not affected by autofluorescence, a recurrent problem in cells that were obtained from urine and the technique provides many internal controls for non-specific binding, and so, we could demonstrate that the different antibodies used indeed bound to different cell populations in these samples.

This work provides an initial comparative analysis of different samples (different time and different patients) of urinary cells of BGC-treated patients. In general, activated immune cells with expression of CD107a and CD69 were identified and a shape consistent with activation (uropod and pseudopod formation) was also observed in microscopy. The myeloid lineage was also abundant, but different phenotypes were detected in different samples, revealing a high heterogeneity between patients.

A striking finding from these analyses is the presence in many samples of a cell population expressing markers of both granulocytes and monocytes, reminiscent of other cell subtypes that have been defined in inflammatory or tumour microenvironments. One hypothesis was that CD14+CD15+ cells could be MDSC, which derive from a common hematopoietic progenitor cell and can express CD14 and CD15 (31–33). In particular, non-classical CD14+CD15+ MDSC have been described in lung and colon cancer (34, 35). However, with this work, we used an optimised flow cytometry protocol, informed by our CyTOF screening, to demonstrate
that CD14+CD15+ cells express markers of both neutrophils and APCs, likely representing a cell type described as antigen-presenting cells (APC)-like hybrid tumour associated neutrophils (TANs). APC-like hybrid TANs have been proposed to differentiate from classical neutrophils by exposure to tumour-derived cytokines, including IFN-γ and GM-CSF, and to possess enhanced anti-tumour properties, like antigen presentation and cross-presentation (36, 37). In the bladder cancer patient urine analysed here, CD15+CD14+ cells also expressed CD16, CD11c and HLA-DR. In flow cytometry, CD14+ monocytes were easily distinguished from the double positive CD14+CD15+ granulocytes (putatively TAN). Whether this population could also have anti-tumour activities has not been addressed and should be the goal of future experiments. In these proposed new investigations, functional studies to distinguish between the activating or suppressor role of these cells will be performed. We propose that these populations could help to define new markers that aid the classification of patients as responder or non-responder, perhaps even to detect early the development of unwanted effects like infection spread. Thus, new studies are planned to evaluate the association of these populations with disease outcome in a larger cohort of patients.

Notably, lymphocytes were not abundant in these samples. Several factors could explain this: 1. Lymphocytes could still be attached to the bladder mucosa; 2. Lymphocytes could die in urine or not be recruited to urine; 3. Epitopes could be lost. Indeed, we have observed that certain clones of anti-CD3 antibodies lose the ability to recognise T cells after they are incubated in urine for 2 hours (not shown). Further, we could amplify CD56 and CD3 genes in some pellets of urine cells, suggesting that some subjects have lymphocytes present. CD3 T cells found in urine samples were usually CD4+ although in some patients CD8 could also be detected. Further supporting the idea that some epitopes may be lost in urine, CD15 was not detected as easily as CD66b by flow cytometry even though both markers should stain the same population, and CD14 was not as bright in CyTOF as it was by flow cytometry. Together, these data suggest that antibody staining can be affected in urine samples. Other studies, using CyTOF and NGS, revealed changes in particular subsets of T lymphocytes in patient peripheral blood samples, specifically NKT cells, central memory CD4+ T cells, CD8+ T cells and regulatory T cells (Treg) (38).

Our analyses of qPCR confirmed the results obtained by CyTOF. We could identify three subjects who showed distinct cell population distribution compared to other patients. In general, patients responding well to the BCG therapy had fewer cells at the beginning of the treatment and developed primarily granulocyte populations in further weeks. This suggests that the composition of urinary cells may be related to the clinical outcome of the patient and could predict response to treatment; however, a larger study is needed in order to definitively establish the value of such biomarkers.

In this study, we have developed protocols that allow the follow-up of bladder cancer patients using flow cytometry of urine cells and gene expression analysis by PCR. The data complement our previous findings showing that cytokines are detectable 7 days after instillations with BCG, and that patients releasing very high amounts of CXCL10 had a more exacerbated immune response sometimes detrimental for the continuation of the treatment (14). We propose that the analysis, in combination, of cells and soluble factors will aid significantly in evaluating the response of bladder cancer patients to BCG therapy.

Further, flow cytometry, ELISA and PCR are standard techniques used in every hospital facilitating the study of high numbers of patients.

In conclusion, although we could not definitively establish links between treatment outcome and donor phenotypes in this challenging pilot study, we were able to identify atypical leukocyte populations possibly related to tumour microenvironment. This work establishes that it is possible to analyse cells released in patient urine by both flow cytometry and CyTOF and that these analyses can provide valuable information on both the intensity and the quality of the immune response leading to either clearance of the tumour or bacterial spread. The optimisation of the analysis techniques described here will facilitate the study of larger patient cohorts to test the utility of candidate biomarkers as indicators of treatment outcome.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Institutional Review Boards: CEI La Paz Hospital HULP-1067 Feb 8th 2011; revised by CEI Infanta Sofia Hospital and CSIC Local Ethical Committee; HULP-2338, April 25th 2016. The patients/participants provided their written informed consent to participate in this study.

Author contributions

EC, CS, LS, EV, TR, HR, and MV-G performed experiments and analysed data. GE, EG-C, SL-C, MA-M, Ali, Ale, LM-P and MV-G selected, acquired and processed patient samples. LM-P, CB, and MV-G provided material support and supervised the study. CB, MV-G, and LM-P conceived and designed the study; EC, LM-P, CB, and MV-G wrote the manuscript. All authors contributed to the article and approved the submitted version.
Acknowledgments

The authors would like to thank the collaboration of patients and nurses from Infanta Sofia and La Paz Hospitals; the confocal microscopy, electron microscopy and flow cytometry services at the CNB; all the members of the Blish’s laboratory for help and advice on CyTOF experiments.

References

1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol (2017) 71:96–108. doi:10.1016/j.eururo.2016.06.010
2. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors. J Urol (1976) 116:180–3. doi:10.1016/S0022-5347(17)58737-6
3. Babjuk M, Bohn A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol (2017) 71:1447–61. doi:10.1016/j.eururo.2016.05.041
4. Gandhi NM, Morales A, Lamm DL. Bacillus calmette-guerin immunotherapy for genitourinary cancer. BJU Int (2013) 112:288–97. doi:10.1111/bju.12154
5. Sylvestre RJ. How well can you actually predict which non-muscle-invasive bladder cancer patients will progress? Eur Urol (2011) 60:431–3. doi:10.1016/j.eururo.2011.06.081
6. Kamat AM, Li R, O’Donnell MA, Black PC, Roupret M, Catto JW, et al. Predicting response to intravesical bacillus calmette-guerin immunotherapy: Are we there yet? a systematic review. Eur Urol (2017) 73(5):738–48. doi:10.1016/j.eururo.2017.10.003
7. Perez-Jacoiste Asin MA, Fernandez-Ruiz M, Lopez-Medrano F, Lumbraezas C, Tejido A, San Juan R, et al. Bacillus calmette-guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer. Incidence, risk factors, and outcome in a single-institution series and review of the literature. Med (Baltimore) (2014) 93:236–54. doi:10.1097/MD.0000000000001119
8. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus calmette-guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 147:396–600. doi:10.1016/s0022-5347(17)7316-0
9. Larsen ES, Nordholm AC, Lillebaek T, Holden IK, Johansen IS. The epidemiology of bacillus calmette-guerin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int (2019) 124(6):910–16. doi:10.1111/bju.14793
10. Sylvestre RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Boutfioua C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol (2006) 49:466–5; discussion 475-7. doi:10.1016/j.eururo.2005.12.031
11. Cbander S, Sylvestre RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. And risk groups for predicting recurrence, progression, and disease specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus calmette-guerin. Eur Urol (2016) 69:60–9. doi:10.1016/j.eururo.2015.06.045
12. Fernandez-Gomez J, Madero R, Solsona E, Urda M, Martinez-Pineiro L, Gonzalez M, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus calmette-guerin: the CUETO scoring model. J Urol (2009) 182:2195–203. doi:10.1016/j.juro.2009.07.016
13. Bisiaux A, Thounou N, Timsit MO, Eladawi A, Chang HH, Mapes J, et al. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer. J Urol (2009) 181:1571–80. doi:10.1016/j.juro.2008.11.124
14. Ashira O, Esteso G, Garcia-Cuesta EH, Castellano E, Samba C, Escudero-Lopez E, et al. BCG Therapy of bladder cancer stimulates a prolonged release of the chemoattractant CXCL10 (IP10) in patient urine. Cancers (2019) 11(7):940–58. doi:10.3390/cancers11070940
15. Kamat AM, Briggsman J, Urbauer DL, Svatek R, Noguera Gonzalez GM, Anderson R, et al. Cytokine panel for response to intravesical therapy (CyPRIT): Nomogram of changes in urinary cytokine levels predicts patient response to bacillus calmette-guerin. Eur Urol (2016) 69:197–200. doi:10.1016/j.eururo.2015.06.023
16. Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol (2018) 15:615–25. doi:10.1038/s41568-018-0055-4
17. Redelman Sidi G, Gluckman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev (2014) 11:153–62. doi:10.1038/nrr14014.15
18. Suitmann H, Riemensberger J, Betsien G, Schmalz D, Stockle M, Jocham D, et al. Neutrophil granulocytes are required for effective bacillus calmette-guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res (2006) 66:8250–7. doi:10.1158/0008-5472.CAN-06-1416
19. Kumar P, John V, Gupta A, Bhaskar S. Enhanced survival of BCG-stimulated dendritic cells: Involvement of anti-apoptotic proteins and NF-kappaB. Biol Open (2018) 7(6) bio032045 doi:10.1242/bio.032045

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.970931/full#supplementary-material
20. Brandau S, Bohle A. Activation of natural killer cells by bacillus calmette-guerin. *Eur Urol* (2001) 39:518–24. doi: 10.1016/S0302-2838(01)00009-X

21. Brandau S, Riemensberger J, Jacobson M, Kemp D, Zhao W, Zhao X, et al. NK cells are essential for effective BCG immunotherapy. *Int J Cancer* (2001) 92:697–702. doi: 10.1002/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z

22. Garcia-Cuesta EM, Lopez-Cobo S, Alvarez-Maestro M, Esteso G, Romera-Cardenas G, Rey M, et al. NKG2D is a key receptor for recognition of bladder cancer cells by IL-2-Activated NK cells and BCG promotes NK cell activation. *Front Immunol* (2015) 6:284. doi: 10.3389/fimmu.2015.01293

23. Garcia-Cuesta EM, Esteso G, Ashiru O, Lopez-Cobo S, Alvarez-Maestro M, Linares A, et al. Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes. *Oncoimmunology* (2017) 6:e1293212. doi: 10.1080/2162402X.2017.1293212

24. De Boer EC, De Jong WH, van der Meijden AP, Steenbergen PA, Witjes JA, Vegt PD, et al. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus calmette-guerin. *Cancer Immunol Immunother* (1991) 33:411–6. doi: 10.1007/BF01741603

25. Strauss-Albee DM, Fukuyama J, Liang BC, Yao Y, Jarrell JA, Drake AL, et al. Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility. *Sci Trans Med* (2015) 7:297ra115. doi: 10.1126/scitranslmed.aac5722

26. Finck R, Simonds EF, Jager A, Krishnaswamy S, Sachs K, Fantl WJ, et al. Normalization of mass cytometry data with bead standards. *Cytometry A* (2013) 83:483–94. doi: 10.1002/cyto.a.22271

27. Amir el AD, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. *Nat Biotechnol* (2013) 31:545–52. doi: 10.1038/nbt.2594

28. Palmer S, Litvinova K, Rafailov EU, Nabi G. Detection of urinary bladder cancer cells using redox ratio and double excitation wavelengths autofluorescence. *Biosens Bioelectron* (2015) 69:977–86. doi: 10.1016/j.bios.2015.06.043

29. Fienberg HG, Simonds EF, Fantl WJ, Nokan GP, Bodenmiller B. A platinum-based covalent viability reagent for single-cell mass cytometry. *Cytometry A* (2012) 81:467–75. doi: 10.1002/cyto.a.22067

30. Liu Y, Lu J, Huang Y, Ma L. Clinical spectrum of complications induced by intravesical immunotherapy of bacillus calmette-guerin for bladder cancer. *J Oncol* (2019) 2019:6230409. doi: 10.1155/2019/6230409

31. Gabriovich DI. Myeloid-derived suppressor cells. *Cancer Immunol Res* (2017) 5:3–8. doi: 10.1159/000469866.CIR-16-0297

32. Bruno A, Mortara L, Raci D, Noonan DM, Albinia A. Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: Roles in tumor progression. *Front Immunol* (2019) 10:771. doi: 10.3389/fimmu.2019.00771

33. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun* (2016) 7:12150. doi: 10.1038/ncomms12150

34. Mandruzzato S, Solito S, Falasi E, Francescato S, Chiarion-Sileni V, Macellini S, et al. RALPH α+ myeloid-derived suppressor cell expansion in cancer patients. *J Immunol* (2009) 182:6562–8. doi: 10.4049/jimmunol.0803833

35. Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albésiano E, Fu J, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. *J Clin Invest* (2013) 123:1580–9. doi: 10.1172/JCI60083

36. Kheittivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, et al. Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDNa1 heterozygous del(5q) MDS. *Blood* (2014) 124:780–90. doi: 10.1182/blood-2014-01-552463

37. Singhal S, Bhojnagarwala PS, O’Brien S, Moon EK, Garfall AL, Rao AS, et al. Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer. *Cancer Cell* (2016) 30:120–35. doi: 10.1016/j.ccell.2016.06.001

38. Lim CJ, Nguyen PHD, Wasser M, Kumar P, Lee YH, Nasir NJM, et al. Immunological hallmarks for clinical response to BCG in bladder cancer. *Front Immunol* (2021) 11. doi: 10.3389/fimmu.2020.615094

COPYRIGHT © 2022 Castellano, Samba, Esteso, Simpson, Vendrame, García-Cuesta, López-Cobo, Alvarez-Maestro, Linares, Leibar, Ranganath, Reburn, Martinez-Piñeiro, Blash and Valeś-Gómez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.